- Apnimed eyes up to $160M IPO to prep for sleep apnea drug launchIf the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.BioSpace · 1h ago↗ source
- Oak Hill takes SPAC track to Nasdaq with Roche asset in towOak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.BioSpace · 1h ago↗ source
- As pharma descends on China for deals, BIOSECURE Act raises intellectual property riskWhen signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.BioSpace · 7h ago↗ source